ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended September 2023, ResMed (RMD) reported revenue of $1.1 billion, up 16% over the same period last year. EPS came in at $1.64, compared to $1.51 in the year-ago quarter.
The reported revenue represents a surprise of +0.51% over the Zacks Consensus Estimate of $1.1 billion. With the consensus EPS estimate being $1.63, the EPS surprise was +0.61%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
U.S., Canada, and Latin America- Devices: $345.90 million versus $381.59 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.
U.S., Canada, and Latin America- Masks: $292.50 million versus $269.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +22.6% change.
Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care: $324.70 million versus $305.24 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +21.9% change.
Combined Europe, Asia, and other markets- Devices: $218.80 million compared to the $201.54 million average estimate based on four analysts. The reported number represents a change of +22.9% year over year.
Combined Europe, Asia, and other markets- Masks: $105.80 million versus $103.70 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.8% change.
U.S., Canada, and Latin America- Total: $638.40 million versus $650.65 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -6.7% change.
Global revenue- Devices: $564.70 million compared to the $583.13 million average estimate based on four analysts. The reported number represents a change of +9.1% year over year.
Global revenue- Software as a Service: $139.30 million compared to the $140.43 million average estimate based on four analysts. The reported number represents a change of +31.5% year over year.
Global revenue- Total Sleep and Respiratory Care: $963 million compared to the $955.89 million average estimate based on four analysts. The reported number represents a change of +14.1% year over year.
Global revenue- Masks: $398.30 million versus the four-analyst average estimate of $372.76 million. The reported number represents a year-over-year change of +21.8%.
View all Key Company Metrics for ResMed here>>>
Shares of ResMed have returned -5.5% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ResMed Inc. (RMD) : Free Stock Analysis Report
